InvestorsHub Logo
Followers 17
Posts 1419
Boards Moderated 0
Alias Born 12/16/2011

Re: None

Saturday, 03/31/2018 1:39:43 PM

Saturday, March 31, 2018 1:39:43 PM

Post# of 11968
Rumous circulating that Boston Scientific $BSX may still be interested in a Buy Out of NVCN. New price targets came out on Thursday morning after $NVCN ER, Leerink Partners maintained their Outperform rating and issued a $2 price target, Canaccord Genuity came out with a Buy rating and a $0.50 PT, both well above Thursday's $0.061 closing price. Their new CEO / President (as of January 22/2018) Fred Colen ( see bio image at end of this post) spent 8 years as CFO at Boston Scientific, many cannot understand why he would leave that job, to take on a job at NVCN, many say it's to facilitate the buy out..possibly. It's also amazing to see how many other employees have ties to $BSX and the fact that $BSX laid off 300 employees 4 days ago, March 27th, 2018 source: https://www.massdevice.com/boston-scientific-lays-off-nearly-300-from-valencia-neuromod-facilities/ , perhaps to make room for the takeover of $NVCN ?? They also already own 15% of NVCN. If you have any other questions, I would be happy to post it... cheers.







Link to management team:
http://www.neovasc.com/heart-valve-bovine-tissue-tmvi-coronary-sinus-reduction/management/